[HTML][HTML] Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101)
…, R Dorland, J Van Kregten, F Manca, DJ Vugts… - PloS one, 2014 - journals.plos.org
Brain cancer is a devastating disease affecting many people worldwide. Effective treatment
with chemotherapeutics is limited due to the presence of the blood-brain barrier (BBB) that …
with chemotherapeutics is limited due to the presence of the blood-brain barrier (BBB) that …
Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of …
…, T Nayak, DJ Vugts, C Dunn, M Bolijn, J Benz… - …, 2017 - Taylor & Francis
We developed cergutuzumab amunaleukin (CEA-IL2v, RG7813), a novel monomeric CEA-targeted
immunocytokine, that comprises a single IL-2 variant (IL2v) moiety with abolished …
immunocytokine, that comprises a single IL-2 variant (IL2v) moiety with abolished …
[HTML][HTML] Fluorine-18 labelled building blocks for PET tracer synthesis
…, AJ Poot, RVA Orru, AD Windhorst, DJ Vugts - Chemical Society …, 2017 - pubs.rsc.org
… Danielle J. Vugts received her PhD in organic chemistry from the VU University Amsterdam,
The Netherlands under the supervision of Prof. Orru. During a post-doctoral period at the VU …
The Netherlands under the supervision of Prof. Orru. During a post-doctoral period at the VU …
Study of 89Zr-pembrolizumab PET/CT in patients with advanced-stage non–small cell lung cancer
…, R Boellaard, I Bahce, DJ Vugts… - Journal of Nuclear …, 2022 - Soc Nuclear Med
The tumor programmed death ligand 1 (PD-L1) proportion score is the current method for
selecting non–small cell lung cancer (NSCLC) patients for single-agent treatment with …
selecting non–small cell lung cancer (NSCLC) patients for single-agent treatment with …
[HTML][HTML] Immuno-positron emission tomography with zirconium-89-labeled monoclonal antibodies in oncology: what can we learn from initial clinical trials?
…, OS Hoekstra, NH Hendrikse, DJ Vugts… - Frontiers in …, 2016 - frontiersin.org
Selection of the right drug for the right patient is a promising approach to increase clinical
benefit of targeted therapy with monoclonal antibodies (mAbs). Assessment of in vivo …
benefit of targeted therapy with monoclonal antibodies (mAbs). Assessment of in vivo …
[HTML][HTML] Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for 89Zr …
DJ Vugts, C Klaver, C Sewing, AJ Poot… - European journal of …, 2017 - Springer
Purpose All clinical 89 Zr-immuno-PET studies are currently performed with the chelator
desferrioxamine (DFO). This chelator provides hexadentate coordination to zirconium, leaving …
desferrioxamine (DFO). This chelator provides hexadentate coordination to zirconium, leaving …
[HTML][HTML] PET imaging of microglial activation—beyond targeting TSPO
Neuroinflammation, which involves microglial activation, is thought to play a key role in the
development and progression of neurodegenerative diseases and other brain pathologies. …
development and progression of neurodegenerative diseases and other brain pathologies. …
A Universal Procedure for the [18F]Trifluoromethylation of Aryl Iodides and Aryl Boronic Acids with Highly Improved Specific Activity
…, AD Windhorst, RVA Orru, DJ Vugts - Angewandte …, 2014 - Wiley Online Library
Herein, we describe a valuable method for the introduction of the [ 18 F]CF 3 group into
arenes with highly improved specific activity by the reaction of [ 18 F]trifluoromethane with aryl …
arenes with highly improved specific activity by the reaction of [ 18 F]trifluoromethane with aryl …
[HTML][HTML] 89Zr-cetuximab PET imaging in patients with advanced colorectal cancer
…, EC Gootjes, MC Huisman, DJ Vugts… - Oncotarget, 2015 - ncbi.nlm.nih.gov
Monoclonal antibodies (mAbs) against the epidermal growth factor receptor (EGFR) are
used in the treatment of advanced colorectal cancer (mCRC). Approximately 50% of patients …
used in the treatment of advanced colorectal cancer (mCRC). Approximately 50% of patients …
PD-L1 PET/CT Imaging with Radiolabeled Durvalumab in Patients with Advanced-Stage Non–Small Cell Lung Cancer
…, R Boellaard, DE Oprea-Lager, DJ Vugts… - Journal of Nuclear …, 2022 - Soc Nuclear Med
Better biomarkers are needed to predict treatment outcome in non–small cell lung cancer (NSCLC)
patients treated with anti–programmed death-1/programmed death-ligand 1 (PD-1/…
patients treated with anti–programmed death-1/programmed death-ligand 1 (PD-1/…